Shareholder Votes

TTEC Holdings, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026. at the 2026-05-21 meeting.

“2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026. The appointment was ratified with the votes cast as follows: For Against Abstain Broker Non-Votes 42,778,390 52,826 2,321 0”

TTEC Holdings, Inc. shareholders approved Election of seven directors to serve until the next annual meeting of stockholders or until their successors are duly appointed or elected and qualified. at the 2026-05-21 meeting.

“1. To elect seven directors to serve until the next annual meeting of stockholders or until their successors are duly appointed or elected and qualified. Each director was elected with the votes cast as follows: Nominee For Withheld Broker Non-Votes Kenneth D. Tuchman 36,953,095 313,246 5,567,196 Steven J. Anenen 35,408,875 1,857,466 5,567,196 Tracy L. Bahl 36,890,430 375,911 5,567,196 Gregory A. Conley 35,979,990 1,286,351 5,567,196 Robert N. Frerichs 33,501,450 3,764,891 5,567,196 Marc L. Holtzman 35,225,147 2,041,194 5,567,196 Gina L. Loften 37,077,969 188,372 5,567,196”

QUANTA SERVICES, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-21 meeting.

“Ratification of Appointment of Independent Registered Public Accounting Firm (Item 3) The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for fiscal year 2026 was ratified with the vote totals, rounded to the nearest whole share, as set forth in the table below: Number of Votes Cast For Number of Votes Cast Against Withhold /Abstentions Broker Non-Votes 125,199,372 8,114,219 67,276 —”

QUANTA SERVICES, INC. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-21 meeting.

“Advisory Vote on Executive Compensation (Item 2) The advisory resolution approving the Company’s executive compensation as set forth in the 2026 Proxy Statement was approved with the vote totals, rounded to the nearest whole share, as set forth in the table below: Number of Votes Cast For Number of Votes Cast Against Withhold / Abstentions Broker Non-Votes 114,220,186 7,122,529 231,119 11,807,033”

QUANTA SERVICES, INC. shareholders approved Election of Directors at the 2026-05-21 meeting.

“Election of Directors (Item 1) The following ten director nominees were elected as directors of the Company to serve one-year terms expiring at the 2027 Annual Meeting of Stockholders. The vote totals for each director, rounded to the nearest whole share, are set forth in the table below: Nominee: Number of Votes Cast For Number of Votes Cast Against Withhold / Abstentions Broker Non-Votes Earl C. Austin, Jr. 121,035,028 481,029 57,777 11,807,033 Warner L. Baxter 119,732,272 1,600,979 240,583 11,807,033 Doyle N. Beneby 118,416,075 3,093,186 64,573 11,807,033 Bernard Fried 116,964,232 4,237,535 372,067 11,807,033 Worthing F. Jackman 106,953,127 14,239,457 381,249 11,807,033 Joseph Kim 121,230,587 279,793 63,454 11,807,033 Holli C. Ladhani 121,354,250 153,836 65,748 11,807,033 Jo-ann M. dePass Oslovsky 121,206,221 305,528 62,085 11,807,033 R. Scott Rowe 118,160,620 3,172,592 240,622 11,807,033 Martha B. Wyrsch 118,718,836 2,790,359 64,639 11,807,033”

ALNYLAM PHARMACEUTICALS, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditors at the 2026-12-31 meeting.

“3. The Company’s stockholders ratified the appointment by the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 119,847,735 5,937,274 31,695 0”

ALNYLAM PHARMACEUTICALS, INC. shareholders approved Non-binding advisory vote on compensation of named executive officers.

“2. The Company’s stockholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 111,772,389 8,552,534 41,495 5,450,286”

ALNYLAM PHARMACEUTICALS, INC. shareholders approved Re-election of three Class I directors.

“1. The Company’s stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Stuart A. Arbuckle 115,269,659 5,068,463 28,296 5,450,286 Yvonne L. Greenstreet, M.D. 119,787,307 513,049 66,062 5,450,286 Elliott Sigal, M.D., Ph.D. 107,495,421 12,844,836 26,161 5,450,286”

PCB BANCORP shareholders approved Ratification of the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-27 meeting.

“Proposal No.3 Ratification of the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 Vote Type Total Shares Votes For 10,015,747 Votes Against 12,926 Votes Abstain 403 Broker Non-Vote — The vote required to approve this proposal was the affirmative vote of a majority of the votes cast on the proposal. Accordingly, this proposal was approved.”

PCB BANCORP shareholders approved Advisory vote on executive compensation at the 2026-05-27 meeting.

“Proposal No.2 Advisory vote on executive compensation Vote Type Total Shares Votes For 8,493,476 Votes Against 138,194 Votes Abstain 10,060 Broker Non-Vote 1,387,346 The vote required to approve this proposal was the affirmative vote of a majority of the votes cast on the proposal. Accordingly, this proposal was approved.”

PCB BANCORP shareholders approved Election of directors at the 2026-05-27 meeting.

“Proposal No.1 Election of directors of the Company Nominee Votes For Votes Withheld Broker Non-Vote Kijun Ahn 8,555,450 86,280 1,387,346 Daniel Cho 8,632,164 9,566 1,387,346 Haeyoung Cho 8,602,111 39,619 1,387,346 Janice Chung 8,632,060 9,670 1,387,346 Henry Kim 8,604,697 37,033 1,387,346 Sang Young Lee 8,009,952 631,778 1,387,346 Hong Kyun “Daniel” Park 8,386,020 255,710 1,387,346 Don Rhee 8,559,278 82,452 1,387,346 Each of the nominees noted above was elected to serve as members of the board of directors of the Company until the Company’s next annual meeting of shareholders and until their successors are duly elected and qualified.”

Nauticus Robotics, Inc. shareholders approved Approval of a proposal to adjourn the Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, one or more of the other proposals to be voted on at the Meetin at the 2026-05-27 meeting.

“Proposal 6: Approval of a proposal to adjourn the Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, one or more of the other proposals to be voted on at the Meeting. For Against Abstain 8,923,833 3,129,150 375,675”

Nauticus Robotics, Inc. shareholders approved Approval of an amendment to the Company's 2022 Omnibus Incentive Plan to increase the number of available shares to 6,000,000 at the 2026-05-27 meeting.

“Proposal 5: Approval of an amendment to the Company’s 2022 Omnibus Incentive Plan to increase the number of available shares to 6,000,000. For Against Abstain Broker Non-Votes 1,912,375 999,547 96,147 9,420,589”

Nauticus Robotics, Inc. shareholders rejected Approval of a proposal to approve the increase in the number of shares of authorized Common Stock from 625,000,000 to 1,500,000,000 at the 2026-05-27 meeting.

“Proposal 4: Approval of a proposal to approve the increase in the number of shares of authorized Common Stock from 625,000,000 to 1,500,000,000. For Against Abstain 8,259,900 3,940,828 227,930”

Nauticus Robotics, Inc. shareholders approved Approval of a proposal authorizing the Board of Directors of the Company to enact one or more reverse splits of its shares at a ratio between one to 5 and one to 250 in the Board's discretion at the 2026-05-27 meeting.

“Proposal 3: Approval of a proposal authorizing the Board of Directors of the Company to enact one or more reverse splits of its shares at a ratio between one to 5 and one to 250 in the Board’s discretion. For Against Abstain 8,257,578 4,054,838 116,242”

Nauticus Robotics, Inc. shareholders approved Ratification of the appointment of WithumSmith + Brown as the Company's independent registered accounting firm for 2026 at the 2026-05-27 meeting.

“Proposal 2: Ratification of the appointment of WithumSmith + Brown as the Company’s independent registered accounting firm for 2026. For Against Abstain 10,819,830 1,529,990 78,838”

Nauticus Robotics, Inc. shareholders approved Election of two Class I Directors, to serve until the 2029 Annual Meeting of Shareholders at the 2026-05-27 meeting.

“Proposal 1: Election of two Class I Directors, to serve until the 2029 Annual Meeting of Shareholders. Nominee For Withheld Broker Non-Votes Jim Bellingham 2,584,928 423,141 9,420,589 Adam Sharkawy 2,564,737 443,332 9,420,589”

Immunocore Holdings plc shareholders approved Authorization to make political donations/incur political expenditure at the 2026-05-27 meeting.

“Resolution 10 : To authorize the Company to make political donations/incur political expenditure. The votes were cast as follows: For Against Abstain 38,213,340 82,113 8,387”

Immunocore Holdings plc shareholders approved Approval of directors' remuneration report for 2025 (excluding policy) at the 2026-05-27 meeting.

“Resolution 9 : To approve the directors’ remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 26 to 56 of the 2025 U.K. Annual Report (excluding the directors’ remuneration policy set out on pages A-5 to A-15 of Annex A to the Proxy Statement). The votes were cast as follows: For Against Abstain 29,504,692 8,713,573 85,575”

Immunocore Holdings plc shareholders approved Receive and adopt U.K. statutory annual accounts and reports for 2025 at the 2026-05-27 meeting.

“Resolution 8 : To receive and adopt the U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). The votes were cast as follows: For Against Abstain 38,287,987 944 14,909”

Immunocore Holdings plc shareholders approved Authorization to audit committee to determine U.K. statutory auditors’ remuneration for 2026 at the 2026-05-27 meeting.

“Resolution 7 : To authorize the audit committee to determine the U.K. statutory auditors’ remuneration for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 38,293,269 2,481 8,090”

Immunocore Holdings plc shareholders approved Re-appointment of Deloitte LLP as U.K. statutory auditors at the 2026-05-27 meeting.

“Resolution 6 : To re-appoint Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. The votes were cast as follows: For Against Abstain 38,294,523 966 8,351”

Immunocore Holdings plc shareholders approved Ratification of Deloitte LLP as U.S. independent registered public accounting firm for 2026 at the 2026-05-27 meeting.

“Resolution 5: To ratify the appointment of Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 38,294,666 984 8,190”

Immunocore Holdings plc shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-27 meeting.

“Resolution 4: To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: For Against Abstain 29,682,169 8,600,029 21,642”

Immunocore Holdings plc shareholders approved Re-appointment of Kristine Peterson as director at the 2026-05-27 meeting.

“Resolution 3 : To re-appoint as a director of the Company Kristine Peterson. The votes were cast as follows: For Against Abstain 29,537,800 8,744,383 21,657”

Immunocore Holdings plc shareholders approved Re-appointment of William Pao as director at the 2026-05-27 meeting.

“Resolution 2 : To re-appoint as a director of the Company William Pao, M.D., Ph.D. The votes were cast as follows: For Against Abstain 38,040,755 254,852 8,233”

Immunocore Holdings plc shareholders approved Re-appointment of Siddharth Kaul as director at the 2026-05-27 meeting.

“Resolution 1 : To re-appoint as a director of the Company Siddharth Kaul. The votes were cast as follows: For Against Abstain 38,033,664 261,819 8,357”

NCS Multistage Holdings, Inc. shareholders approved Approve, on an advisory basis, the compensation of the Company’s named executive officers at the 2026-05-27 meeting.

“Proposal 3 — Approve, on an advisory basis, the compensation of named executive officers For 1,938,033 Against 3,111 Abstentions 1,635 Broker Non-Votes 285,928”

NCS Multistage Holdings, Inc. shareholders approved Ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-05-27 meeting.

“Proposal 2 — Ratification of Appointment of Independent Registered Public Accounting Firm For 2,226,925 Against 849 Abstentions 933 Broker Non-Votes —”

NCS Multistage Holdings, Inc. shareholders approved Election of two Class III Directors nominated by the Board of Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified at the 2026-05-27 meeting.

“Proposal 1 — Election of Directors Broker Names For Withheld Non-Votes John Deane 1,800,311 142,468 285,928 W. Matt Ralls 1,858,268 84,511 285,928”

Perspective Therapeutics, Inc. shareholders approved Advisory vote on frequency of advisory stockholder votes on executive compensation at the 2026-05-27 meeting.

“The stockholders of the Company voted, on a non-binding advisory basis, on how frequently future non-binding advisory votes on the compensation of the Company’s named executive officers should be held. The votes were cast as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 76,479,166 274,495 364,497 165,067 20,599,237”

Perspective Therapeutics, Inc. shareholders approved Ratification of appointment of WithumSmith+Brown, PC as independent registered public accounting firm at the 2026-05-27 meeting.

“The stockholders of the Company ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Perspective Therapeutics, Inc. shareholders approved Election of Directors at the 2026-05-27 meeting.

“The stockholders of the Company elected Lori A. Woods, Heidi Henson, Maya Martinez-Davis, Frank Morich, M.D., Ph.D., Johan (Thijs) Spoor and Robert Froman Williamson, III to the Company’s Board of Directors”

TRINET GROUP, INC. shareholders approved Ratification of Deloitte & Touche LLP as independent auditor at the 2026-05-27 meeting.

“Proposal 3. Stockholders ratified the selection by the Finance and Audit Committee of the Board of Directors of the Company of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Total 41,815,075 582,335 49,978 0 42,447,388”

TRINET GROUP, INC. shareholders approved Advisory vote on executive compensation at the 2026-05-27 meeting.

“Proposal 2. Stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Total 38,448,545 903,509 31,258 3,064,076 42,447,388”

TRINET GROUP, INC. shareholders approved Election of Directors at the 2026-05-27 meeting.

“Proposal 1 . Stockholders elected each of the three nominees below as directors to serve until the Company’s 2029 Annual Meeting of Stockholders or until his or her respective successor has been duly elected and qualified. The voting results were as follows: Director Name Votes For Votes Withheld Broker Non-Votes Total Michael J. Angelakis 38,391,874 991,438 3,064,076 42,447,388 David C. Hodgson 37,885,852 1,497,460 3,064,076 42,447,388 Jacqueline Kosecoff 38,866,465 516,847 3,064,076 42,447,388 Michael Q. Simonds 38,933,678 449,634 3,064,076 42,447,388”

Civeo Corp shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026 and authorization to determine compensation at the 2026-12-31 meeting.

“Proposal 4 - To ratify the appointment of Ernst & Young LLP as Civeo’s independent registered public accounting firm for the year ending December 31, 2026 and until the next annual general meeting of shareholders and to authorize the directors of Civeo, acting through the Audit Committee, to determine the remuneration to be paid to Ernst & Young LLP for 2026: For Withheld Broker Non-Votes 10,096,589 4,228 --”

Civeo Corp shareholders approved Amendment to 2014 Equity Participation Plan to increase shares available by 520,920.

“Proposal 3 – To approve an amendment to the Plan to increase the number of shares available for issuance thereunder by 520,920 shares, subject to adjustment in accordance with the terms of the Plan: For Against Abstain Broker Non-Votes 8,240,482 53,383 310,708 1,496,244”

Civeo Corp shareholders approved Advisory vote on compensation of named executive officers.

“Proposal 2 - To approve, on an advisory basis, the compensation of the named executive officers: For Against Abstain Broker Non-Votes 8,247,893 33,269 323,411 1,496,244”

Civeo Corp shareholders approved Election of the three Class II and Class III nominees to the Board.

“The voting results for each proposal are as follows: Proposal 1 - To elect the three Class II and Class III nominees to the Board: For Withheld Broker Non-Votes Richard A. Navarre 8,406,487 198,086 1,496,244 Martin A. Lambert 8,417,605 186,968 1,496,244 Constance B. Moore 8,418,306 186,267 1,496,244 Bradley J. Dodson 8,572,412 32,161 1,496,244 Daniel B. Silvers 8,293,243 311,330 1,496,244 Timothy O. Wall 8,562,700 41,873 1,496,244”

Nuvation Bio Inc. shareholders approved To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. at the 2026-05-21 meeting.

“Proposal No. 3 - To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.”

Nuvation Bio Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-05-21 meeting.

“Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Nuvation Bio Inc. shareholders approved Election of Directors at the 2026-05-21 meeting.

“Proposal No. 1 - Election of Directors. The individuals listed below were elected at the Annual Meeting to serve as directors of the Company until the Company’s 2029 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal.”

LTC PROPERTIES INC shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-05-20 meeting.

“Proposal No. 3: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of LTC for fiscal 2026, based upon the following votes: For Against Abstentions Broker Non-Votes 38,142,277 1,191,990 95,221 -0-”

LTC PROPERTIES INC shareholders approved Advisory vote on executive compensation at the 2026-05-20 meeting.

“Proposal No. 2: Stockholders approved, on an advisory basis, the compensation of the named executive officers of LTC, based upon the following votes: For Against Abstentions Broker Non-Votes 31,454,030 1,228,903 106,967 6,639,588”

LTC PROPERTIES INC shareholders approved Election of Directors at the 2026-05-20 meeting.

“Proposal No. 1: Stockholders elected six directors to serve on the Board of Directors for the ensuing year and until the election and qualification of their respective successors, based upon the following votes: Director Nominee For Against Abstentions Broker Non-Votes Cornelia Cheng 32,478,949 247,411 63,540 6,639,588 David L. Gruber 32,591,576 146,564 51,760 6,639,588 Jeffrey C. Hawken 32,395,204 329,919 64,777 6,639,588 Bradley J. Preber 32,548,503 173,361 68,036 6,639,588 Wendy L. Simpson 32,285,974 453,380 50,546 6,639,588 Timothy J. Triche, M.D. 31,621,007 1,108,278 60,615 6,639,588”

Apple Hospitality REIT, Inc. shareholders approved Advisory resolution to approve the compensation paid to the Company's named executive officers at the 2026-05-22 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 175,328,993 5,940,374 730,287 20,674,943”

Apple Hospitality REIT, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm to serve for 2026 at the 2026-05-22 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES 199,438,485 2,704,182 531,930 -”

Apple Hospitality REIT, Inc. shareholders approved Election of eight directors to the Board of Directors at the 2026-05-22 meeting.

“NOMINEE FOR WITHHELD BROKER NON-VOTES Glenn W. Bunting 177,756,332 4,243,322 20,674,943”

HEALTHCARE SERVICES GROUP INC shareholders approved Shareholder approval to amend the 2020 Omnibus Plan to increase the number of shares of Common Stock that are available for issuance thereunder by 2,500,000 at the 2026-05-26 meeting.

“Proposal No. 4 — Amendment to the 2020 Omnibus Plan The proposal relating to shareholder approval to amend the 2020 Omnibus Plan to increase the number of shares of Common Stock that are available for issuance thereunder by 2,500,000 has received a majority of the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 59,690,433 2,747,530 61,769 3,607,184”